TMX Newsfile Cannabis Ancillary Service Provider News Releases

Quinsam Reports Q4/2025 Results

Mon, 27 Apr 2026 08:00:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION BY ANY UNITED STATES NEWS DISTRIBUTION SERVICEToronto, Ontario--(Newsfile Corp. - April 27, 2026) - Quinsam Capital Corporation (CSE: QCA) ("Quinsam" or the "Company") is announcing its Q4/2025 results, with net income of $0.4 million ($0.01 per share basic, $0.01 fully diluted) versus a net loss of $4.3 million ($0.04 per share basic, $0.01 fully diluted) in Q4/2024. Investors can access the Company's full financial statements on...

Red Light Holland Announces Filament Health Shareholder Approval of Acquisition

Mon, 27 Apr 2026 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - April 27, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light") and Filament Health Corp. (OTC: FLHLF) ("Filament") are pleased to announce that, further to their joint press release dated March 10, 2026 and March 23, 2026, Filament's shareholders (the "Filament Shareholders") have approved each of the matters voted on at the Filament annual general and special meeting ("Filament Meeting") held on April 24, 2026, including...

Red Light Holland Showcases Growing Clinical Demand for Filament Health's PEX010 with New and Repeat University Shipments

Fri, 24 Apr 2026 08:26:00 -0400

Toronto, Ontario--(Newsfile Corp. - April 24, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is pleased to highlight continued expansion and execution of clinical supply shipments of PEX010, a botanical psilocybin drug candidate developed by Filament Health Corp., to leading Canadian research institutions.Following its press release dated April 7, 2026, Red Light is highlighting recent accomplishments and ongoing momentum, including completed...

Red Light Holland Highlights U.S. FDA-Authorized Study Supporting Multi-Session Psilocybin Therapy using Filament Health's Patented PEX010 Botanical Drug Candidate

Mon, 20 Apr 2026 07:30:00 -0400

Study conducted under U.S. FDA Investigational New Drug (IND) authorization by Dr. Anthony Back at the University of WashingtonSecond psilocybin session showed meaningful improvements in anxiety, depression, and overall psychological outcomes, with effects lasting up to 24 weeks69% of participants fell below clinical thresholds for anxiety and depression after second treatmentResearch builds on prior studies utilizing Filament's botanical psilocybin drug candidate, PEX010No serious adverse...

Red Light Holland Reports Continued Expansion of Filament Health's PEX010 Clinical Network with New License Agreements and Research Shipments

Tue, 07 Apr 2026 07:30:00 -0400

Three new license agreements signed and two research shipments completed in March 2026, spanning institutions in Australia, the United Kingdom, and CanadaToronto, Ontario--(Newsfile Corp. - April 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") today announced that Filament Health Corp. ("Filament") signed three new license agreements and completed two research shipments during March 2026, further expanding the global clinical network for...

Red Light Holland to Support University of California San Francisco's Global Psychedelic Study Through Filament Health's Clinical Network

Wed, 01 Apr 2026 09:20:00 -0400

Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") today announced that, through Filament Health Corp. ("Filament"), it will support the Carhart-Harris Lab ("CHL") at the University of California, San Francisco ("UCSF") by providing instructions on how to participate in the CHL Global Psychedelic Study to all researchers and clinicians receiving PEX010, including clinical trials and compassionate use...

Red Light Holland Announces Filament Health Obtains Interim Order for Proposed Arrangement

Mon, 23 Mar 2026 08:15:00 -0400

Toronto, Ontario--(Newsfile Corp. - March 23, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") today announced that, further to the joint press release dated March 10, 2026, the Supreme Court of British Columbia issued an interim order (the "Interim Order") in connection with the previously announced acquisition by Red Light of all the issued and outstanding common shares of Filament (the...

Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate

Wed, 18 Mar 2026 08:15:00 -0400

AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industryToronto, Ontario and Arlington, Massachusetts--(Newsfile Corp. - March 18, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Kala Bio, Inc. (NASDAQ: KALA) ("Kala Bio") today announced that Red Light has engaged Kala Bio's Researgency.ai agentic...

RETRANSMISSION: Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation

Wed, 11 Mar 2026 07:30:00 -0400

Expands Red Light's drug development platform with Filament's GMP manufacturing, Health Canada Dealer's Licence, Health Canada and FDA-authorized clinical programs, and 76 issued patents covering natural psilocybin manufacturing and formulationCombines Red Light's operational scale, global brand presence, and real-world microdosing data with Filament's pharmaceutical R&D capabilities and patented PEX010 botanical psilocybin drug candidateAll-share transaction in which existing Red Light...

Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation

Tue, 10 Mar 2026 16:40:00 -0400